Clinical trial
Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome
NCT00464373 · Daniel Stephan Engeler, Other · Terminated
Key facts
| NCT number | NCT00464373 |
|---|---|
| Title | Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome |
| Official title | Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial |
| Acronym | BTX-URO-01 |
| Lead sponsor | Daniel Stephan Engeler, Other |
| Collaborators | Allergan Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Prostatitis |
| Intervention type | Drug |
| Interventions | Botulinum Toxin Type A, Placebo |
| Enrollment | 11 |
| Start date | Apr 1, 2007 |
| Primary completion | May 1, 2013 |
| Completion | Jun 1, 2013 |
| First posted | Apr 23, 2007 |
| Last update posted | Feb 3, 2014 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: